Spots Global Cancer Trial Database for Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
Official Title: A Phase II Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride Versus Placebo When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone Metastases Treated With Hormonal Treatment Background Therapy
Study ID: NCT02258464
Conditions
Study Description
Brief Summary: The objective of this study was to assess efficacy and safety of radium-223 dichloride in subjects with human epidermal growth factor receptor 2 negative (HER2 negative) hormone receptor positive breast cancer with bone metastases treated with hormonal treatment background therapy
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
, Bakersfield, California, United States
, La Jolla, California, United States
, Aurora, Colorado, United States
, New Haven, Connecticut, United States
, Cedar Rapids, Iowa, United States
, Annapolis, Maryland, United States
, Ann Arbor, Michigan, United States
, Pontiac, Michigan, United States
, Saint Louis, Missouri, United States
, Pittsburgh, Pennsylvania, United States
, Houston, Texas, United States
, Linz, Oberösterreich, Austria
, Innsbruck, , Austria
, Winnipeg, Manitoba, Canada
, London, Ontario, Canada
, Newmarket, Ontario, Canada
, Toronto, Ontario, Canada
, Ostrava, , Czechia
, Praha 2, , Czechia
, Copenhagen, , Denmark
, Herlev, , Denmark
, Helsinki, , Finland
, Tampere, , Finland
, Angers Cedex, , France
, Saint Cloud, , France
, Tübingen, Baden-Württemberg, Germany
, Bonn, Nordrhein-Westfalen, Germany
, Essen, Nordrhein-Westfalen, Germany
, Kowloon, , Hong Kong
, Cork, , Ireland
, Dublin, , Ireland
, Afula, , Israel
, Haifa, , Israel
, Jerusalem, , Israel
, Jerusalem, , Israel
, Kfar Saba, , Israel
, Ramat Gan, , Israel
, Tel Aviv, , Israel
, Zerifin, , Israel
, Busan, , Korea, Republic of
, Daegu, , Korea, Republic of
, Incheon, , Korea, Republic of
, Seoul, , Korea, Republic of
, Seoul, , Korea, Republic of
, Seoul, , Korea, Republic of
, Nieuwegein, , Netherlands
, Zwolle, , Netherlands
, Oslo, , Norway
, Bialystok, , Poland
, Gdynia, , Poland
, Warszawa, , Poland
, Singapore, , Singapore
, L'Hospitalet de Llobregat, Barcelona, Spain
, A Coruña, , Spain
, Barcelona, , Spain
, Barcelona, , Spain
, Madrid, , Spain
, Madrid, , Spain
, Madrid, , Spain
, Málaga, , Spain
, Sevilla, , Spain
, Zaragoza, , Spain
, Aarau, Aargau, Switzerland
, Taipei, , Taiwan
, Plymouth, Devon, United Kingdom
, Northwood, Middlesex, United Kingdom
, Nottingham, Nottinghamshire, United Kingdom
, Taunton, Somerset, United Kingdom
, Cottingham, , United Kingdom
, Merseyside, , United Kingdom
, Sheffield, , United Kingdom
Contact Details
Name: Bayer Study Director
Affiliation: Bayer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
